Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke

E-ISSN： 1873-4286|18|25|3677-3684

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.25, 2012-07, pp. : 3677-3684

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tissue-type plasminogen activator as a therapeutic target in stroke

By Gravanis Iordanis Tsirka Stella E

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 2, 2008-02 ,pp. : 159-170

Informa Healthcare

Access to resources Recommend Favorite

Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 2, 2013-04 ,pp. : 155-169

Bentham Science Publishers

Access to resources Recommend Favorite

The complexity of tissue-type plasminogen activator: can serine protease inhibitors help in stroke management?

By Lebeurrier Nathalie Vivien Denis Ali Carine

Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 4, 2004-08 ,pp. : 309-320

Informa Healthcare

Access to resources Recommend Favorite

Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke: A Canadian Healthcare Perspective

By Sinclair S.E.

PharmacoEconomics, Vol. 19, Iss. 9, 2001-01 ,pp. : 927-936

Adis International

Access to resources Recommend Favorite

Tissue Plasminogen Activator (tPA) and Matrix Metalloproteinases in the Pathogenesis of Stroke: Therapeutic Strategies

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 7, Iss. 3, 2008-06 ,pp. : 243-253

Bentham Science Publishers

Access to resources Recommend Favorite